Stephens Inc. AR Sells 25,381 Shares of Geron Co. (NASDAQ:GERN)

Stephens Inc. AR decreased its position in Geron Co. (NASDAQ:GERN) by 35.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,443 shares of the biopharmaceutical company’s stock after selling 25,381 shares during the period. Stephens Inc. AR’s holdings in Geron were worth $206,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of GERN. National Bank of Canada FI lifted its holdings in shares of Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares in the last quarter. Crewe Advisors LLC lifted its holdings in shares of Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 8,700 shares in the last quarter. Kingsview Wealth Management LLC bought a new position in shares of Geron during the 1st quarter valued at about $34,000. American Trust bought a new position in shares of Geron during the 1st quarter valued at about $38,000. Finally, CIBC Asset Management Inc lifted its holdings in shares of Geron by 32.7% during the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Stock Performance

Shares of NASDAQ GERN opened at $4.25 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The stock’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $4.30. Geron Co. has a one year low of $1.64 and a one year high of $5.34. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -13.28 and a beta of 0.52.

Geron (NASDAQ:GERN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The company had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same period in the prior year, the firm posted ($0.08) EPS. Geron’s quarterly revenue was up 17138.4% on a year-over-year basis. On average, equities analysts forecast that Geron Co. will post -0.34 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on GERN. Leerink Partnrs upgraded Geron to a “strong-buy” rating in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Geron in a report on Friday, August 9th. HC Wainwright started coverage on Geron in a research note on Tuesday. They issued a “buy” rating and a $8.00 target price on the stock. StockNews.com upgraded Geron to a “sell” rating in a research note on Monday, August 5th. Finally, Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Geron in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Geron presently has an average rating of “Moderate Buy” and an average price target of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.